β-Amyloid (Aβ) protein is a pivotal pathogenetic factor in Alzheimer’s disease (AD). However, increasing evidence suggests that the brain has to continuously produce excessive Aβ to efficaciously prevent pathogenic micro-organism infections, which induces and accelerates the disease process of AD. Meanwhile, Aβ exhibits activity against herpes simplex virus type 1 (HSV-1) and influenza A virus (IAV) replication, but not against other neurotropic viruses. Enterovirus A71 (EV-A71) is the most important neurotropic enterovirus in the post-polio era. Given the limitation of existing research on the relationship between Aβ and other virus infections, this study aimed to investigate the potent activity of Aβ on EV-A71 infection and extended the potential function of Aβ in other unenveloped viruses may be linked to Alzheimer's disease or infectious neurological diseases.
Methods
Aβ peptides 1–42 are a major pathological factor of senile plaques in Alzheimer’s disease (AD). Thus, we utilized Aβ1–42 as a test subject to perform our study. The production of monomer Aβ1–42 and their high-molecular oligomer accumulations in neural cells were detected by immunofluorescence assay, ELISA, or Western blot assay. The inhibitory activity of Aβ1–42 peptides against EV-A71 in vitro was detected by Western blot analysis or qRT-PCR. The mechanism of Aβ1–42 against EV-A71 replication was analyzed by time-of-addition assay, attachment inhibition assay, pre-attachment inhibition analysis, viral-penetration inhibition assay, TEM analysis of virus agglutination, and pull-down assay.
Results
We found that EV-A71 infection induced Aβ production and accumulation in SH-SY5Y cells. We also revealed for the first time that Aβ1–42 efficiently inhibited the RNA level of EV-A71 VP1, and the protein levels of VP1, VP2, and nonstructural protein 3AB in SH-SY5Y, Vero, and human rhabdomyosarcoma (RD) cells. Mechanistically, we demonstrated that Aβ1–42 primarily targeted the early stage of EV-A71 entry to inhibit virus replication by binding virus capsid protein VP1 or scavenger receptor class B member 2. Moreover, Aβ1–42 formed non-enveloped EV-A71 particle aggregates within a certain period and bound to the capsid protein VP1, which partially caused Aβ1–42 to prevent viruses from infecting cells.
Conclusions
Our findings unveiled that Aβ1–42 effectively inhibited nonenveloped EV-A71 by targeting the early phase of an EV-A71 life cycle, thereby extending the potential function of Aβ in other non-envelope viruses linked to infectious neurological diseases.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
Aβ
β-Amyloid protein
AD
Alzheimer’s disease
AMP
Antimicrobial peptide
EV-A71
Enterovirus A 71
CCK
Cell Counting Kit
EM
Enteroviral meningitis
qRT-PCR
Real-time reverse transcription-PCR
SCARB2
Scavenger receptor class B member 2
TEM
Electron Microscope
Background
β-Amyloid (Aβ) is identified as an essential pathological factor involved in Alzheimer's disease (AD) [1, 2]. Nevertheless, a deeper understanding of the relationship between AD and pathogenic microbial infections is prompting further exploration of the physiological function of Aβ. Aβ, a novel defined antimicrobial peptide (AMP), also reportedly exhibits antiviral action against herpes simplex virus type 1 (HSV-1) and influenza A virus (IAV) [3‐6]. The oligomerization of Aβ peptide prevents bacteria from binding to bacterial-surface carbohydrates, which is also the partial mechanism of Aβ in exerting its anti-herpes virus effect [4, 5, 7]. Meanwhile, Bourgade et al. suggested that Aβ may be associated with another favorable antiviral mechanism in addition to the carbohydrate-binding-mediated antiviral pathway [3].
Enterovirus A 71 (EV-A71), a non-enveloped virus with a positive-sense ssRNA genome enclosed within an icosahedron capsid shell, comprises 60 copies of four capsid proteins, VP1, VP2, VP3, and VP4 [8]. For non-enveloped viruses, the binding of receptors is a critical event in the course of infection. EV-A71 utilizes cell-surface glycoproteins as receptors to infect host cells [9, 10]. Scavenger receptor class B member 2 (SCARB2), a type III multichannel membrane glycoprotein, is the main receptor for EV-A71 on target cells [11‐13]. SCARB2 is pivotal in EV-A71’s attachment and uncoating, facilitating efficient EV-A71 infection [14].
Anzeige
Besides causing hand, foot and mouth disease (HFMD), EV-A71 also infects the CNS and induces neurology-related severe diseases [15]. The relationship between EV-A71 and Aβ has not been reported. In the present study, we demonstrated for the first time that EV-A71 infection induced Aβ1–42 production and accumulation and elucidated the mechanism by which Aβ1–42 inhibited EV-A71 replication. Our results revealed that Aβ presented antiviral activity against EV-A71 infection, paving the way for further research on the potential role of Aβ peptides in other brain-infecting viruses.
Methods
Oligomeric synthetic peptide preparation and compounds
Aβ peptides 1–42 are a major pathological factor of senile plaques in AD [16, 17]. Accordingly, we utilized Aβ1–42 as a test subject to perform our study.
Synthetic Aβ1–42 peptides were obtained from Anaspec (Fremont, CA. USA). Dried peptides were solubilized in 150 mM NaCl prior to experimentation. Aβ1–42 was used at 30 µg/mL concentration for the viral life-cycle experiment and 20 µg/mL for the antiviral activity test or pull-down experiment.
Pirodavir was purchased from Biochempartner (Shanghai, China), and NH4Cl was bought from MedChemExpress (USA). Stock solutions of pirodavir (10 mM) and NH4Cl (100 mM) were prepared in dimethyl sulfoxide (Sigma–Aldrich, Carlsbad, CA, USA), respectively. RBV stock solutions (2 mg/mL) were dissolved in a cell culture medium.
Anzeige
Viral strains and cell lines
Human rhabdomyosarcoma (RD) cells and SH-SY5Y cells were bought from the Cellular Cultivation Center of Peking Union Medical College (PUMC) or Chinese Academy of Sciences (CAS) and cultivated in Dulbecco’s adjusted Eagle intermediary comprising 10% fetal bovine serum (FBS; Gibco, USA) and 1% penicillin–streptomycin (Invitrogen, Carlsbad, CA, USA). Vero cells were acquired from the American Type Culture Collection (ATCC), and cultured in modified Eagle’s medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% inactivated FBS (Gibco, Grand Island, NY, USA) and 1% penicillin–streptomycin.
EV-A71 strain H (VR-1432) and Coxsackievirus B3 strain Nancy (VR-30) were purchased from ATCC. CVA16 strain (shzh05-1/GD/CHN/2005) was offered by Dr. Jianwei Wang, Institute of Pathogen Biology, CAS, and PUMC. Entire viral strains were passaged in Vero cells.
Quantification of Aβ1–42 by ELISA
A human Aβ (1–42 aa) Quantikine ELISA Kit (R&D Systems, DAB142) was used to identify human Aβ (aa1–42) in cellular cultivation supernatant under the condition of EV-A71 infection. The experiment was performed per the manufacturer’s instructions.
Cytotoxicity assay
The cytotoxic effects of Aβ1–42 peptides on SH-SY5Y, Vero, and RD cells were evaluated with a Cell-Counting Kit (CCK) (TransGen Biotech, Beijing, China). In a typical procedure, cells were cultured in 96-well plates and indicated concentrations of Aβ1–42 peptides were added for 48 h. Then, 10 µL of CCK solution was added to each cell well. The absorbance of the plates was detected at 450 nm on an Enspire system (PerkinElmer, Waltham, MA, USA) after incubating at 37 °C for 30 min.
Western blot (WB) assay
Total proteins were lysed with an M-PER mammal-protein abstraction reagent containing a halt protease suppressor cocktail (Thermo Fisher Scientific, USA). An equal amount of cell lysate was used in a 10%–12% (w/v) SDS-PAGE gels, electro-transferred onto PVDF membranes (Millipore, USA), and blocked with 5% (w/v) milk at room temperature for 2 h. The films were incubated with the first antibody against EV-A71 VP1 (Abnova, Taipei, China), EV-A71 VP2 (GeneTex, California, USA), EV-A71 3AB (GeneTex, California, USA), SCARB2 (Abcam, UK), Aβ1–42 (CST, USA), and β-actin (CST, USA) overnight at 4 °C. Finally, an ECL identification kit (GE Healthcare Life Sciences, USA) was used with an appropriate second antibody (CST, USA) for 1 h at room temperature [18]. Software “Gel-Pro analyzer” was used to analysis of the optical density ratio of the bands.
To detect of Aβ1–42 monomer (4 kDa), the suspensions were mixed with 1 × loading buffer (containing DTT) and boiled for 10 min. We used 20% Tris–Tricine–SDS-PAGE gels prepared per the manufacturer’s instructions (Solarbio, China). The gels were transferred onto PVDF membranes for 1 h under the condition of 200 mA by using a transfer buffer containing 20% methanol, 190 mM glycine, and 25 mM Tris. The membranes were blocked with 5% (w/v) milk at room temperature for 2 h. The films were incubated with the first antibody against Aβ1–42 (CST, USA) overnight at 4 °C. Finally, an ECL identification kit (GE Healthcare Life Sciences, USA) was used with an appropriate second antibody (CST, USA) for 1 h at room temperature [18].
Immunofluorescence assay and confocal microscopy
SH-SY5Y and Vero cells were infected with EV-A71 (MOI = 1) for 8 h. Cells were fixed with 4% polyoxymethylene for 30 min before the cultivation in 0.1% Triton X-100 for another 20 min. Cells were then blocked and cultivated with an antibody against VP1 and Aβ1–42. After washing in TBS three times, VP1 protein was visualized using an Alexa Fluor 488-conjugated secondary antibody (Invitrogen), whereas Aβ1–42 protein was visualized with Alexa Fluor 594. Cell nuclei were dyed with DAPI (Beyotime, PRC). Images were captured with an Olympus TH4-200 microscope or PE UltraVIEW VOX.
Real-time reverse transcription-PCR (qRT-PCR)
Overall, RNA was extracted with RNeasy Mini Kit (Qian, USA). The level of EV-A71 VP1 RNA was quantified with One-Step qRT-PCR by using primers VP1-forward (5′-GATATCCCACATTCGGTGA-3′) and VP1-reverse (5′-TAGGACACGCTCCATACTCAAG-3′). The level of CVA16 VP1 RNA was identified using primers VP1-forward (5′-GTTATCCCACCTTCGGAGA-3′) and VP1-reverse (5′-TCGGGCATTGACCATAATCTAG-3′). The level of CVB3 VP1 RNA was amplified with forwarding primers VP1 (5′-TGCTCCGCAGTTAGGATTAGC-3′) and reverse VP1 (5′-ACATGGTGCGAAGAGTCTATTGAG-3′). GAPDH mRNA and β-actin mRNA served as an internal control to standardize the examined mRNAs by using primers GAPDH-forward (5′-GAAGGTGAAGGTCGGAGTC-3′). GAPDH-reverse (5′-GAAGATGGTGATGGGATTTC-3′). The relative fold change of the detected RNA specimens was analyzed by the comparative 2−ΔΔCT method [19].
Anzeige
Time-of-addition assay
The virus-replication steps targeted by Aβ1–42 were mapped by identifying the role of sequential supplementation of Aβ1–42 on EV-A71 VP1-level variation. In short, SH-SY5Y cells were subjected to EV-A71 infection (MOI = 10), and Aβ1–42 (30 μg/mL) was supplemented at the time of infection or at a different time post-infection. Entire cells were collected at 8 h post-infection, and VP1 expression was detected by WB assay.
Attachment-inhibition assay
Cell plates were stored at 4 °C for 60 min before starting the assay. SH-SY5Y, Vero, or RD cells were incubated with EV-A71 (MOI = 2.5) and Aβ1–42 (30 µg/mL) at 4 °C for 60 min. Afterwards, cells were washed in cold PBS (pH = 7.4) three times and subjected to a qRT-PCR assay.
Pre-attachment inhibition analysis
The pre-attachment inhibition analysis was designed as two experimental methods to test the various suppression characteristics of Aβ1–42.
For the pre-attachment inhibition assay, EV-A71 virus (MOI = 2.5) was mixed with Aβ1–42 (30 µg/mL) peptides at 4 °C for 1 h and attached to SH-SY5Y or Vero cells in cold 12-well plates at 4 °C for another 1 h. Total cellular RNA was extracted after three washes with cold PBS (pH = 7.4) and analyzed by qRT-PCR.
Anzeige
For the pre attachment inhibition assay of Aβ1–42 peptides, 20 µg/mL Aβ1–42 was incubated with precooled cell plates at 4 °C for 60 min and then washed in cold PBS three times. The processed cells were used in the subsequent pre attachment inhibition assays of the virus.
Virus-penetration inhibition assay
Cells were cultivated with EV-A71 (MOI = 2.5) at 4 °C for 60 min to enable viral attachments, followed by cleaning in cold PBS three times to realize the removal of nonbound viruses. They were subsequently cultivated at 37 °C for 60 min to internalize viruses, and uncoating occurred eventually. After washing the unbound viruses three times, cells were lysed, and the RNA content of EV-A71 was measured by qRT-PCR analysis.
Purification of EV-A71 virions
EV-A71 was propagated in Vero cells at 37 °C for 3 days. The cells were freeze-thawed in three cycles and then centrifuged at 3000 g for 30 min to remove cell debris. EV-A71 was initially concentrated using a 100 kDa centrifugal concentrator (Millipore, Billerica, MA, USA) at 3000 g for 30 min. Then, the virus was sedimented through a 20% density sucrose layer at 4 °C, 14,000 g for 3 h with a Beckman SW41 Ti rotor. Virus fractions at the bottom were harvested and gently resuspended in PBS (pH = 7.4). The purified EV-A71 stock was supplied for transmission electron microscopy (TEM) and pull-down assays [5, 6].
TEM analysis of virus agglutination
The purified EV-A71 stock was cultivated together with Aβ1–42 peptides in PBS (pH = 7.4) at 4 °C for 1 h, absorbed into formvar carbon-coated copper grids for 60 s, and then stained with 1% (w/v) phosphotungstic acid (pH = 6.8) for another 60 s. The grids were desiccated in air atmosphere and imaged with a Tecnai12 TEM (FEI, Eindhoven, Netherlands) with a CCD camera (EMSIS MRADA g3, Germany).
Anzeige
Pull-down assay
For EV-A71 VP1 pull-down assays, 20 µg/mL Aβ1–42 was incubated with protein A/G magnetic beads at 4 °C overnight before adding IgG or purified EV-A71 after cleaning in cold PBS three times. Subsequently, the mixture was cultivated at 4 °C for 2 h. After cleaning in cold PBS three times, the bound virions were detected by WB assay with VP1 antibody.
For the SCARB2 pull-down assays, 6 µg of SCARB2-Myc plasmid or pcDNA 3.1 + vector was transfected into Vero cells and lysed with protein lysate containing protein phosphatase and protease inhibitor at 24 h post-transfection. Subsequently, the lysis buffer supernatant was mixed with Aβ1–42 immobilized magnetic protein A/G magnetic beads at 4 °C for 2 h. The bounded beads were suspended with a 1 × sample loading buffer and boiled for 10 min. The binding of SCARB2 was detected by WB with anti-SCARB2 antibody.
Statistical analysis
The two groups were contrasted by Student’s T-test, and more groups were contrasted through one-way ANOVA using GraphPad Prism 8.0. Asterisks (*) corresponded with p < 0.05 (*), p < 0.01 (**), p < 0.001 (***), and p < 0.0001 (****).
Results
EV-A71 infection increased the production and aggregation of Aβ1–42
To determine whether Aβ expression was altered in response to EV-A71 infection, we used an ELISA assay to detect the secreted expression level of Aβ1–42 in the supernatant of EV-A71-infected SH-SY5Y cells (MOI = 1) and applied immunofluorescence assay to test the intracellular Aβ1–42 expression. As presented in Fig. 1a, compared with mock-infected control, the concentration of secreted Aβ1–42 was significantly higher at 12 h after EV-A71 infection. Moreover, Aβ1–42 was slightly induced after EV-A71 infection, and its expression increased with increased virus dose (Fig. 1b). The accumulation of Aβ1–42 high-molecular-weight oligomer aggregates (~ 70 kDa) was observed by WB assay at 6 and 12 h after EV-A71 infection (MOI = 1) (Fig. 1c). A similar phenomenon has been found in HSV-infected cells [20]. These results suggested that EV-A71 infection can induce Aβ1–42 production and aggregation accumulation.
Fig. 1
Aβ1–42 generation and aggregation were responsive for EV-A71 infection in SH-SY5Y cells. a Production of Aβ1–42 from the supernatant was quantified with an ELISA kit. SH-SY5Y cells were subjected to EV-A71 infection (MOI = 1) and collected at 6 or 12 h post-EV-A71 infection. b Production of intracellular Aβ1–42 was quantified by IFA assay. SH-SY5Y cells were subjected to EV-A71 infection at MOIs of 0.01, 0.1, and 1 for 8 h, respectively. IFA of Aβ1–42 protein was performed with an Alexa Fluor 488-conjugated antibody (green), and the nucleus was dyed with DAPI (blue). c Aβ1–42 high-molecular-weight oligomer accumulation in response to EV-A71 (MOI = 1) at 6 and 12 h after infection was detected by Western blot with anti-Aβ1–42 antibody (~ 70 kDa)
×
Aβ1–42 inhibited EV-A71 replication in vitro
To determine whether Aβ oligomers exerted antiviral activity against EV-A71 infection, we examined the effects of Aβ1–42 oligomerized peptide on EV-A71 replication in neural cells and EV-A71 susceptible cell lines, Vero, and RD cells. To exclude possible cytotoxicity-mediated antiviral effect, we initially determined the cytotoxicity of Aβ1–42 in SH-SY5Y, Vero, and RD cells through CCK assay. Results showed that cell viability was approximately 93%–100% in the treatment of Aβ1–42 for 48 h at concentrations of 30 or 20 µg/mL (Fig. 2a). Accordingly, we applied Aβ1–42 at 20 µg/mL for subsequent antiviral assays. In SH-SY5Y cells, Aβ1–42 and ribavirin (RBV) significantly inhibited the RNA level of EV-A71 VP1 (Fig. 2b), as well as the protein levels of VP1, VP2, and nonstructure protein 3AB (Fig. 2c). The inhibitory percentages of Aβ1-42 on VP1, VP2 and 3AB proteins in SH-SY5Y cells were 42.81%, 43.64%, and 44.16%, respectively. Then, we moved to EV-A71 susceptible cell lines, and results showed that Aβ1–42 and RBV effectively inhibited the expression of VP1, VP2, and 3AB proteins in RD cells. The inhibitory percentages of Aβ1-42 on VP1, VP2 and 3AB proteins in RD cells were 53.50%, 36.36% and 58.57%, respectively. In Vero cells the inhibitory percentages were 45.81%, 71.42%, and 74.00%, respectively (Fig. 2d). This finding suggested that Aβ1–42 inhibited EV-A71 replication independent of cell-line specificity.
Fig. 2
Cytotoxicity and anti-EV-A71 activity of Aβ1–42 in vitro. a Cytotoxicity of Aβ1–42 to multiple cell lines were determined by CCK assay at 48 h post-peptide treatment. b and c SH-SY5Y cells were infected with EV-A71 (MOI = 1) and followed by treatment with Aβ1–42 peptides or RBV (20 µg/mL) for 24 h. The concentrations of EV-A71 VP1 RNA and protein were assayed by qRT-PCR and WB, respectively. d Aβ1–42 peptides or RBV were added to EV-A71-infected Vero (MOI = 0.1) and RD cells (MOI = 0.01) for 24 h. The content of EV-A71 VP1 protein was analyzed by WB. Software “Gel-Pro analyzer” was used to analysis of the optical density ratio of the bands
×
Aβ1–42 targeted the early stage of the EV-A71 life cycle
In deciphering the EV-A71 life cycle stages targeted by Aβ1–42, we performed a time-of-addition experiment. We increased the inoculum to 10 MOI of EV-A71 to ensure a high infection efficiency to assess one-step growth [21]. Aβ1–42 was added at different time points either during or after EV-A71 infection and quantified the viral VP1 protein by WB assay 8 h after EV-A71 infection. As shown in Fig. 3a, when Aβ1–42 was added 1 h during or after EV-A71 infection, the antiviral effect was almost completely lost. This result indicated that Aβ1–42 inhibited EV-A71 infection at the early stage of the virus-replication cycle, possibly inhibiting virus entry.
Fig. 3
Aβ1–42 targeted the attachment and post-attachment phases of EV-A71 infection. a Time-of-addition experiment. SH-SY5Y cells were subjected to EV-A71 infection (MOI = 10) at 0 h time point. At 1 h point, cells were cleaned in PBS buffer and collected at 8 hpi. EV-A71 VP1 was determined by WB assay. The grey column indicates the period in which 30 µg/mL Aβ1–42 peptides were present. b EV-A71 virus (MOI = 2.5) was added to precooled cell plates simultaneously with Aβ1–42 (30 µg/mL) or pirodavir (40 µM) at 4 °C for 1 h. The amounts of cell-bound EV-A71 particles were measured by qRT-PCR. c Precooled cells that adhered to EV-A71 were incubated with Aβ1–42 (30 µg/mL) or NH4Cl (40 µM) at 37 °C for 60 min. The content of vp1 RNA was identified by qRT-PCR
×
To dissect which step of EV-A71 entry was affected by Aβ1–42, we evaluated the process of viral attachment in SH-SY5Y, Vero, and RD cells. In the viral-attachment assay, the content of VP1 RNA was measured by qRT-PCR, and the inhibition of Aβ1–42 on viral attachment was observed in three cell lines (MOI = 2.5). Pirodavir, the known capsid inhibitor of EV-A71, served as the control [22]. Compared with the untreated control, the viral VP1 RNA levels with Aβ1–42 or pirodavir treatments decreased in all three cell lines (Fig. 3b). In the penetration-inhibition assay, we further studied the effect of Aβ1–42 on the EV-A71 RNA level at 1 h post-virus attachment (MOI = 2.5). Figure 3c shows that consistent with NH4Cl treatment [23], Aβ1–42 efficiently downregulated the level of VP1 RNA after EV-A71 attachment in all three cell lines.
Taken together, these results demonstrated that Aβ1–42 primarily targeted EV-A71 attachment, internalization, and uncoating stage to inhibit virus replication.
Aβ1–42 bound to EV-A71 VP1 protein
To further investigate the mechanism by which Aβ1–42 treatment induced EV- A71 entry blockage, we determined whether Aβ1–42 could cause the aggregation of EV-A71 and affect its entry. After incubating Aβ1–42 peptides with EV-A71 for 1 h, the aggregation of EV-A71 particles was observed by TEM assay (Fig. 4a). Moreover, the colocalization of VP1 and Aβ1–42 was observed in SH-SY5Y and Vero cells (Fig. 4b). We further confirmed that Aβ1–42 interacted with EV-A71 capsid protein VP1 by pull-down assay (Fig. 4c). Co-incubation of EV-A71 with Aβ1–42 at 4 °C for 1 h also significantly reduced the infectivity of EV-A71 (Fig. 4d). Consequently, we revealed that Aβ1-42 promoted the aggregation of EV-A71 virus particles and bound to the capsid protein VP1, which partially caused Aβ1–42 to prevent viruses from infecting cells.
Fig. 4
Aβ1–42 induced EV-A71 aggregation and directly bound to VP1. a Purified EV-A71 virus was incubated with Aβ1–42 (20 µg/mL) at 4 °C for 60 min, and EV-A71 aggregation was analyzed by TEM. b SH-SY5Y or Vero cells were subjected to EV-A71 infection (MOI = 2.5) for 8 h, and the co-localization between Aβ1–42 (detected with a 488-conjugated antibody against Aβ1–42, green) and EV-A71 VP1 (Alexafluor594-conjugated antibody against VP1, red) was identified by confocal assay. Images were captured at 100 × magnification with a PE UltraVIEW VOX. c Aβ1–42 (20 µg/mL) was mixed with activated protein A/G magnetic beads overnight at 4 °C. Subsequently, the mixture was cultivated with purified EV-A71 virus (MOI = 1) at 4 °C for h. After cleaning the beads to remove nonbound viruses, the magnetic beads were subjected to precipitation with a magnet holder and assayed by Western blot with VP1 antibody. d Pre-virus attachment inhibition assay of Aβ1–42 showed comparable inhibition capacity against EV-A71 infections. Virus (MOI = 2.5) with or without Aβ1–42 medium incubated at 4 °C for 1 h, followed by infecting precooled cells at 4 °C for another 1 h. The quantity of cell-bound EV-A71 virus was identified by qRT-PCR. Experiments were independently repeated three times
×
Aβ1–42 bound to the EV-A71 receptor SCARB2
The carbohydrate-binding function of Aβ can inhibit microbial infections by targeting glycoproteins on the cell wall of microbes or enveloped viruses [24]. Accordingly, we performed a series of methods to determine whether the antiviral activity of Aβ1–42 was related to SCARB2, which was an attachment and uncoating glycoproteins for EV-A71 infection. We initially performed a pre-Aβ1–42 peptide-attachment assay to determine whether Aβ1–42 pre-interacted with SCARB2 on the cell surface. We pretreated the cells with Aβ1–42 or pirodavir for 1 h and then infected them with EV-A71 (MOI = 2.5). The adsorption of EV-A71 on cellular surfaces was detected by qRT-PCR. The outcomes unveiled that pretreatment with Aβ1–42 significantly suppressed the adsorption of EV-A71 in all three cell lines, whereas pretreatment with pirodavir did not affect EV-A71 adsorption (Fig. 5a). Furthermore, consistent with inhibiting EV-A71, Aβ1–42 also exhibited the same effect on CVA16 but not on CVB3 (Fig. 5b) possibly because SCARB2 was only a receptor of CVA16 rather than CVB3 [11‐13]. We further performed a pull-down experiment to demonstrate whether an interaction existed between Aβ1–42 and SCARB2. Aβ1–42 immobilized magnetic beads were used to pull down SCARB2 protein overexpressed in Vero cells. Results showed that Aβ1–42 could specifically bind to SCARB2 protein (Fig. 5c). These results suggested that Aβ1–42 might inhibit EV-A71 by interacting with SCARB2 to block virus entry.
Fig. 5
Aβ1–42 is directly bonded to SCARB2. a SH-SY5Y, Vero, and RD cells were pretreated with Aβ1–42 (20 µg/mL) or pirodavir (40 µM) at 4 °C for 60 min, followed by EV-A71 infection (MOI = 2.5) at 4 °C for another 1 h. The overall RNA was harvested, and EV-A71 VP1 RNA variation was evaluated by qRT-PCR. b SH-SY5Y cells were subjected to CVA16 or CVB3 infection (MOI = 1) and afterward subjected to Aβ1–42 peptide or RBV treatment (20 µg/mL) for 24 h. The virus VP1 RNA level was analyzed by qRT-PCR. c Vero cells were subjected to SCARB2-myc or pcDNA 3.1 + plasmid transfection for 24 h and lysed with protein lysate containing phosphatase and protease inhibitor. Subsequently, the lysis buffer supernatant was mixed with Aβ1–42 immobilized magnetic beads at 4 °C for 2 h. The bound beads were suspended with a 1 × sample loading buffer and boiled for 10 min. The binding of SCARB2 was detected by WB assay with anti-SCARB2 antibody
×
Discussion
Enterovirus A types, including EV-A71 and CVA16, are primary pathogens related to HFMD and encephalitis, which are typical neural complications from HFMD infection. They are accompanied by complications such as central nervous system (CNS) damage, particularly in East and Southeast Asia [15, 25, 26]. Aβ has long been recognized as a pathogenetic factor for AD. However, the antimicrobial function of Aβ has been gradually revealed recently. Here, we demonstrated for the first time that Aβ1–42 exhibited antiviral activity against EV-A71 and CVA16 infections. The anti-EV-A71 effect of Aβ presented in SH-SY5Y cells, and in Vero and RD cells indicates that Aβ1–42 inhibited EV-A71 replication independent of cell-line specificity. Mechanistically, we revealed that Aβ1–42 interfered with the attachment and uncoating stage of EV-A71 infection. The effect of Aβ1–42 on suppressing viral post-attachment was more effective than the attachment in SH-SY5Y cells, whereas an equal inhibition effect was observed in Vero and RD cells. The reason for this apparent difference in nerve cells remains elusive. Aβ exhibited a direct ability to bind microbial surface carbohydrates, primarily mediating its antimicrobe infection capability. The carbohydrate binding of Aβ promoted self-fibrillization, leading to the aggregation of enveloped viruses such as HSV-1, HHV6, and IAV, thereby reducing viral infectivity [4, 6, 27, 28]. However, we discovered that Aβ1–42 also induced a slight aggregation of non-envelope virus EV-A71 after co-incubating for 1 h and bound to virus capsid protein VP1 performed by pull-down assay. Meanwhile, either the binding to VP1 or the aggregation of EV-A71 may lead to the impairment of virus attachment (Fig. 4d). Bourgade et al. suggested that the carbohydrate-binding of Aβ may not be the only pathway to target herpesviruses. Previous research has assumed that Aβ, which has high sequence homology to the HSV-1-gB membrane-proximal region, targets HSV-1 by competing for binding gB's fusion loops, thereby preventing the HSV-1 fusion cell process [29]. Based on VP1 of EV-A71, which is not a glycoprotein, the binding between VP1 and Aβ may exist in other pathways. Accordingly, we speculated that a noncarbohydrate binding region of Aβ1–42 may mediate the targeting of EV-A71 capsid protein VP1.
In HSV-1 and IAV, the present research showed that Aβ inhibited virus replication outside the cells but not when peptides were added after virus infection. In contrast to previous reports, we discovered that the antiviral action of Aβ could effectually occur inside the target cells (Figs. 2 and 3c). Unlike enveloped viruses, the cellular entry of non-enveloped viruses primarily relies on the binding to cell surface virus receptors. SCARB2, a membrane glycoprotein, mediates viral entry into the cell and is a common receptor for all enterovirus A virus. Consistent with the glycoprotein-binding function, Aβ could interact with SCARB2 and inhibit EV-A71 attachment and entry (Fig. 5). We further found that Aβ1–42 inhibited CVA16 rather than CVB3 replication (Fig. 5b), possibly because SCARB2 was not a receptor for CVB3. Hsu et al. revealed that Aβ could bind to the spike protein S1 sub-unit (S1) of the SARS-CoV-2 and the viral receptor ACE2, enhancing the interaction of the S1 protein with ACE2 and increasing the virus entry along with intracellular IL-6 production [30]. Figure 5a indicates that pretreating with Aβ1–42 peptides in various cell lines led to evident reductions in EV-A71 RNA levels. This finding suggested that Aβ exerted a competitive combination with SCARB2 instead of strengthening the binding of EV-A71 to SCARB2. Further investigation is required to confirm the interference of Aβ1–42 on the binding of the virus to SCARB2. Recent research has suggested that the VP1 GH and VP2 EF loops of EV-A71 interact with SCARB2 and further facilitate the low-pH uncoating of the virus in endosomes/lysosomes [31]. Our results showed that Aβ1–42 bound to VP1 protein but not VP2 (Additional file 1: Fig. S1), indicating that the viral VP1 GH loop may play a key role in mediating the interaction of VP1 and Aβ1–42. Our results further showed that Aβ1–42 interacted with SCARB2 or VP1. However, further studies are needed to confirm whether these two interactions were competitive or synergistic.
Toczylowski K et al. measured Aβ1–42, a traditional AD biomarker, in children with enteroviral meningitis caused by echovirus. The CSF concentration of Aβ1–42 was decreased when compared with the control group without CNS infection. In contrast, other biomarker concentrations are unchanged [32]. Thus, an enteroviral infection may lead to a specific impact on Aβ1–42 production. Our results showed that Aβ1–42 generation and accumulation were induced at 12 h after EV-A71 infection in SH-SY5Y cell lines (Fig. 1). The findings of Toczylowski et al., together with ours, reveal the distinct effect of various enteroviruses infection on Aβ1–42 production. Nevertheless, whether Aβ production and further aggregation is a protective immune response against the invasion of foreign pathogens such as EV-A71 infection requires further exploration.
Over the past few years, several infection factors have been proposed to be associated with AD development [33]. Most past research has focused on the relation between Aβ1–42 and HSV-1. Little is known about enteroviruses that exert a similar inflammatory influence on CNS due to HSV infection [24, 33]. Thus, more detailed studies on the specific binding of the amino acid region of Aβ1–42 to capsid VP1 protein or virus receptor SCARB2 should be performed. Apart from SCARB2, PSGL-1 is also a typical glycoprotein receptor of EV-A71. However, PSGL-1 is expressed by macrophages in the intestinal mucosa and lymph-node dendritic cells, and it plays a key role in trafficking inflammation stimulated by infection [34]. We did not use PSGL-1-expression cell lines in this research and will explore it in a follow-up work if needed. The previous discoveries of Bourgade et al. have revealed that Aβ1–42 can not inhibit non-enveloped human adenovirus replication in vitro. Our findings unveiled that Aβ1–42 can sufficiently inhibit non-enveloped EV-A71 effectively, thereby extending the potential function of Aβ in other non-enveloped viruses linked to infectious neurological diseases.
Conclusion
We demonstrated for the first time that Aβ1–42 exhibited antiviral activity against EV-A71 infection. We primarily revealed that Aβ1–42 interfered with the attachment and uncoating stage of EV-A71 infection. Given that non-polio enteroviruses including EV-A71 are known to display strong neurotropism, the role of Aβ in EV-A71 infection is worth investigating.
Acknowledgements
Not applicable.
Declarations
Consent for publication
All authors consent to the publication of the manuscript.
Animal and human rights statement
This article does not contain any studies with human or animal subjects performed by any of the authors.
Competing interests
The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.
Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.
Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.
Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.
Update Innere Medizin
Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.
